Raising Health The Science and Supply of GLP-1s with Brooke Boyarsky Pratt
15 snips
Jun 4, 2024 
Brooke Boyarsky Pratt, CEO of knownwell, discusses obesity medicine, patient-centric care, and the future of metabolic health. Topics include GLP-1s for insulin regulation, improving patient access to medications, and the founder's transition from business to healthcare passion.
AI Snips
Chapters
Transcript
Episode notes
Weight-Inclusive Approach Benefits
- Weight-inclusive care, focusing on wellness at any size, leads to better health outcomes than weight-normative approaches.
- Comprehensive obesity treatment includes medication, nutrition, sleep, movement, behavioral health, and remote patient monitoring.
Discovering GLP-1s in 2018
- Brooke learned about obesity medicine and GLP-1s in 2018 from an obesity specialist, which transformed her understanding of treatment options.
- That early exposure to medications like Ozempic influenced her vision for improving metabolic health care.
Realistic GLP-1 Drug Expectations
- GLP-1 drugs do not work as a miracle cure for everyone; 40-60% of patients may not achieve significant weight loss.
- Proper patient selection, symptom management, and emphasis on quality nutrition, especially protein intake, are critical for success.